Effects of Oral L-Arginine on Everyday Persistent Fatigue, Sleep, and Post-Exercise Lactate Recovery in Community-Dwelling Working-Age Adults: A Double-Blind, Placebo-Controlled Randomized Trial.
L-arginine supplementation at 6 g/day for 8 weeks reduced fatigue severity relative to placebo and was well-tolerated, but mean FSS scores remained above the enrollment threshold, indicating a reduction in, rather than resolution of, persistent fatigue.
Key Findings
Results
L-arginine 6 g/day reduced Fatigue Severity Scale (FSS) scores more than placebo at Week 8, while 3 g/day did not differ from placebo.
8-week randomized, double-blind, placebo-controlled trial in adults aged 30-59 years with persistent fatigue (FSS total ≥ 27); 120 randomized, 119 analyzed.
FSS change at Week 8 was -6.41 with 6 g/day versus -2.23 with placebo (Holm-adjusted p = 0.024).
The 3 g/day dose did not differ from placebo on the primary endpoint.
Results
The improvement in Checklist Individual Strength (CIS) with 6 g/day did not survive multiplicity adjustment.
CIS was a secondary endpoint.
Holm adjustment for multiplicity was applied across comparisons.
Results
Sleep quality (PSQI) improved nominally at both doses of L-arginine.
3 g/day: p = 0.007; 6 g/day: p = 0.045.
These are reported as nominal improvements (not stated as surviving Holm adjustment).
Results
L-arginine 6 g/day lowered blood lactate measures during and after a standardized submaximal treadmill run compared with placebo.
Treadmill run at ~70% VO2max for 30 minutes with lactate kinetics measured.
Total lactate area under the curve was lower with 6 g/day (Holm-adjusted p = 0.041).
15-minute recovery lactate was lower with 6 g/day (Holm-adjusted p = 0.002).
Results
Resting plasma nitrite did not differ between L-arginine and placebo.
Nitrite was assessed as a resting biomarker.
The abstract reports no difference, so the lactate and fatigue effects are not accompanied by a change in resting nitrite.
Results
L-arginine was well-tolerated with no serious adverse events.
Doses tested were 3 g/day and 6 g/day for 8 weeks.
No serious adverse events occurred.
Conclusions
Mean FSS scores remained above the enrollment threshold after treatment, so L-arginine reduced rather than resolved persistent fatigue.
Enrollment threshold was FSS total ≥ 27.
The authors state this indicates a reduction in, rather than resolution of, persistent fatigue.
What This Means
This study tested whether taking the amino acid L-arginine could ease everyday, ongoing fatigue in working-age adults. 120 people aged 30-59 with persistent fatigue took 3 grams a day, 6 grams a day, or a placebo for 8 weeks, without knowing which one they received. Fatigue was measured with a standard questionnaire, and some participants' blood lactate (a by-product of exertion) was tracked after a standardized treadmill run.
The 6 gram daily dose reduced fatigue scores more than placebo (a drop of about 6.4 points versus 2.2), while the 3 gram dose did not. Sleep quality scores improved at both doses, though these results were less statistically firm. At 6 grams, blood lactate was lower overall during exercise and 15 minutes into recovery than with placebo. No serious side effects were reported.
This research suggests L-arginine at a higher dose may modestly lessen persistent fatigue, but it did not eliminate it: average scores stayed above the level used to define fatigue at the start. Some secondary measures, such as another fatigue questionnaire, did not hold up after statistical correction. The trial was short (8 weeks), so longer and larger studies would be needed to confirm the findings.
Check Your Own Numbers
Upload your bloodwork. We'll cross-reference your results against this study and 4,700 others.
Kang E, Hong S, Yoon N, Lee N, Kim B. (2026). Effects of Oral L-Arginine on Everyday Persistent Fatigue, Sleep, and Post-Exercise Lactate Recovery in Community-Dwelling Working-Age Adults: A Double-Blind, Placebo-Controlled Randomized Trial.. Nutrients. https://doi.org/10.3390/nu18203375